There is an important distinction between diagnostic and screening tests, and they have different issues in regards to decision making-although the person making treatment decisions should ultimately be guiding the ship, according to Bryan Loy, MD, MBA.
There is an important distinction between diagnostic and screening tests, and they have different issues in regards to decision making—although the person making treatment decisions should ultimately be guiding the ship, according to Bryan Loy, MD, MBA.
He added that he’s always surprised to learn the lack of medical history that is taken, for example, in conjunction with a BRCA1 or BRCA2 test.
“It feels like we’ve still got a long way to go in creating some accountability and a measurement system and education system to get people ordering them thoughtfully,” Dr Loy said.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen